The two trials evaluating lacutamab, an investigational therapy developed to treat T-cell lymphomas, were put on partial hold by the FDA. The patient died of hemophagocytic lymphohistiocytosis, which is…
Welcome to the Rare Classroom, a new series from Patient Worthy. Rare Classroom is designed for the curious reader who wants to get informed on some of the rarest, most…
In a recent news release from global specialty pharmaceutical company Kyowa Kirin International PLC ("Kyowa Kirin"), the company announced the release of new real-world data on POTELIGEO (mogamulizumab) for patients…
According to a story from pm360online.com, the drug developer Innate Pharma SA recently announced that its experimental therapy IPH4102 has been granted Fast Track designation from the US Food and…
Each year the Food and Drug Administration approves dozens of new therapies to fulfill unmet needs for various patient populations. It's just been published that in 2018 they approved a…
Dr. Louis J. DeGennaro, who is the CEO and President of the Leukemia & Lymphoma Society, has recently contributed a blog post on the organization's website. In this post, Dr.…
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
